CytomX Therapeutics, Inc. (FRA:6C1)

Germany flag Germany · Delayed Price · Currency is EUR
3.604
+0.032 (0.90%)
At close: Dec 1, 2025
279.37%
Market Cap625.40M
Revenue (ttm)96.85M
Net Income (ttm)23.88M
Shares Outn/a
EPS (ttm)0.20
PE Ratio26.19
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume831
Open3.604
Previous Close3.572
Day's Range3.604 - 3.604
52-Week Range0.384 - 3.822
Betan/a
RSI62.24
Earnings DateMar 6, 2026

About CytomX Therapeutics

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBO... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 121
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6C1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.